

**Clinical trial results:**

**A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia.**

**Summary**

EudraCT number	2004-000750-22
Trial protocol	DE
Global end of trial date	14 February 2008

**Results information**

Result version number	v1 (current)
This version publication date	13 March 2016
First version publication date	13 March 2016

**Trial information****Trial identification**

Sponsor protocol code	D1441C00112
-----------------------	-------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00090324
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	AstraZeneca
Sponsor organisation address	One MedImmune Way, Gaithersburg, United States, 20878
Public contact	Heather Wray, Research Physician, AstraZeneca, 46 0 31 706 4082, Heather.Wray@Astrazeneca.com
Scientific contact	Heather Wray, Research Physician, AstraZeneca, 46 0 31 706 4082, Heather.Wray@Astrazeneca.com
Sponsor organisation name	AstraZeneca
Sponsor organisation address	One MedImmune Way, Gaithersburg, United States, 20878
Public contact	Heather Wray, Research Physician, AstraZeneca, 46 0 31 706 4082, Heather.Wray@Astrazeneca.com
Scientific contact	Heather Wray, Research Physician, AstraZeneca, 46 0 31 706 4082, heather.wray@astrazeneca.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000324-PIP01-08
Does article 45 of REGULATION (EC) No	No

1901/2006 apply to this trial?	
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 February 2008
Is this the analysis of the primary completion data?	Yes
Primary completion date	14 February 2008
Global end of trial reached?	Yes
Global end of trial date	14 February 2008
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to compare the efficacy of 2 doses of quetiapine (400 mg/day and 800 mg/day) with that of placebo in the treatment of schizophrenia in adolescent patients as assessed by the change from baseline to Day 42 in the Positive and Negative Syndrome Scale (PANSS) total score (primary outcome variable).

Protection of trial subjects:

The final study protocol, including the final version of the Informed Consent Form (ICF), was approved or given a favorable opinion in writing by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) as appropriate.

The Principal Investigator was responsible for informing the IRB or IEC of any amendment to the protocol in accordance with local requirements. The Principal Investigator was also responsible for providing the IRB with reports of any serious adverse drug reactions from any other study conducted with the investigational product. Progress reports and notifications of serious adverse drug reactions were provided to the IRB or IEC according to local regulations and guidelines.

The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization (ICH)/Good Clinical Practice (GCP) and applicable regulatory requirements and the AstraZeneca policy on Bioethics.

The Principal Investigator at each center ensured that both the patient (assent) and the parent or legal guardian (consent) were given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 October 2004
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 62
--------------------------------------	-------------------

Country: Number of subjects enrolled	Puerto Rico: 5
Country: Number of subjects enrolled	Poland: 9
Country: Number of subjects enrolled	Russian Federation: 39
Country: Number of subjects enrolled	Serbia: 26
Country: Number of subjects enrolled	Ukraine: 27
Country: Number of subjects enrolled	India: 8
Country: Number of subjects enrolled	Malaysia: 8
Country: Number of subjects enrolled	Philippines: 31
Country: Number of subjects enrolled	South Africa: 6
Country: Number of subjects enrolled	Germany: 1
Worldwide total number of subjects	222
EEA total number of subjects	10

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	222
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This multicenter study was conducted between 1 October 2004 and 20 June 2007. 268 patients were enrolled from one of 43 international centers

### Pre-assignment

Screening details:

This study had a 28 day washout period and a 6-week double-blind treatment period where patients were randomized to quetiapine 400 mg/day, 800 mg/day or placebo.

### Pre-assignment period milestones

Number of subjects started	268 <sup>[1]</sup>
Number of subjects completed	222

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Protocol deviation: 42
Reason: Number of subjects	Patient Moved: 2
Reason: Number of subjects	Adverse event, non-fatal: 2

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The number of subjects reported to have started the pre-assignment period is 268, which includes 46 patients who were initially found eligible but were not enrolled into the study. The worldwide number enrolled in the trial is 222 which is the number of subjects who were actually entered into the study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Quetiapine 400 mg/day

Arm description:

Quetiapine

Arm type	Experimental
Investigational medicinal product name	Quetiapine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One tablet once a day

<b>Arm title</b>	Quetiapine 800 mg/day
------------------	-----------------------

Arm description:

Quetiapine

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Quetiapine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet once a day

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Placebo

Arm type	Placebo
Investigational medicinal product name	plaaacebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

one tablet once a day

<b>Number of subjects in period 1</b>	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo
Started	73	74	75
Completed	56	61	47
Not completed	17	13	28
Consent withdrawn by subject	3	3	8
Adverse event, non-fatal	5	7	2
Reasons Unrelated to Treatment	3	1	1
Lost to follow-up	-	-	2
Protocol deviation	6	2	15

## Baseline characteristics

### Reporting groups

Reporting group title	Quetiapine 400 mg/day
Reporting group description: Quetiapine	
Reporting group title	Quetiapine 800 mg/day
Reporting group description: Quetiapine	
Reporting group title	Placebo
Reporting group description: Placebo	

Reporting group values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo
Number of subjects	73	74	75
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	73	74	75
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous   Units: years			
arithmetic mean	15.5	15.5	15.3
standard deviation	± 1.3	± 1.3	± 1.4
Gender, Male/Female			
Number			
Units: Participants			
Female	30	30	31
Male	43	44	44
Race/Ethnicity, Customized Units: Subjects			
Asian	15	13	12
Black or African American	7	9	11
White	45	44	48
Unknown or Not Reported	6	8	4

Reporting group values	Total		
Number of subjects	222		
Age categorical Units: Subjects			
In utero	0		

Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	222		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous   Units: years arithmetic mean standard deviation	-		
Gender, Male/Female			
Number			
Units: Participants			
Female	91		
Male	131		
Race/Ethnicity, Customized Units: Subjects			
Asian	40		
Black or African American	27		
White	137		
Unknown or Not Reported	18		

## End points

### End points reporting groups

Reporting group title	Quetiapine 400 mg/day
Reporting group description:	Quetiapine
Reporting group title	Quetiapine 800 mg/day
Reporting group description:	Quetiapine
Reporting group title	Placebo
Reporting group description:	Placebo

### Primary: PANSS total score

End point title	PANSS total score
End point description:	Change
End point type	Primary
End point timeframe:	Baseline to 42 days

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	55	43	
Units: Rating Scale				
least squares mean (standard error)	-27.3 ( $\pm$ 2.6)	-28.4 ( $\pm$ 1.8)	-19.2 ( $\pm$ 3)	

### Statistical analyses

Statistical analysis title	Change from Baseline in PANSS Total Score
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.043
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-8.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.1
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	4

<b>Statistical analysis title</b>	Change from Baseline in PANSS Total Score
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.009
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-9.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.2
upper limit	-2.4
Variability estimate	Standard error of the mean
Dispersion value	3.5

### Secondary: Response at day 42

End point title	Response at day 42
End point description:	
Percentage of patients with $\geq 30\%$ reduction from baseline in PANSS total score	
End point type	Secondary
End point timeframe:	
Day 42	

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	55	43	
Units: Participants	28	22	17	

### Statistical analyses

<b>Statistical analysis title</b>	Percent Responders
Statistical analysis description:	
30% decrease from baseline to end of study in PANSS total score	
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.125
Method	GEE
Parameter estimate	Odds ratio (OR)
Point estimate	1.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	4.13

<b>Statistical analysis title</b>	Percentage Responders
Statistical analysis description:	
30% reduction in PANSS total score from baseline to end of study	
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.675
Method	GEE
Parameter estimate	Odds ratio (OR)
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	2.87

## Secondary: PANSS postive symptom subscale

End point title	PANSS postive symptom subscale
End point description:	
Change	
End point type	Secondary
End point timeframe:	
Baseline to Day 42	

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	55	43	
Units: Rating Scale				
least squares mean (standard error)	-8.6 ( $\pm$ 0.7)	-9.3 ( $\pm$ 0.6)	-6.5 ( $\pm$ 0.9)	

## Statistical analyses

Statistical analysis title	PANSS Positive Symptom Subscale
Statistical analysis description: Change from baseline to end of study	
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.9
upper limit	-0.8
Variability estimate	Standard error of the mean
Dispersion value	1.1

Statistical analysis title	PANSS Positive Symptom Subscale
Statistical analysis description: Change from baseline to end of study	
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.075
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	1.1

---

**Secondary: PANSS negative symptom subscale**

---

End point title	PANSS negative symptom subscale
-----------------	---------------------------------

End point description:

Change

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 42

---

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	55	43	
Units: Rating Scale				
least squares mean (standard error)	-6.4 (± 0.8)	-6.2 (± 0.6)	-5.1 (± 0.7)	

**Statistical analyses**

<b>Statistical analysis title</b>	Change in PANSS Negative Symptom Subscale
-----------------------------------	---

Statistical analysis description:

Change from baseline to end of study

Comparison groups	Quetiapine 400 mg/day v Placebo
-------------------	---------------------------------

Number of subjects included in analysis	97
---	----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority
---------------	-------------

P-value	= 0.239
---------	---------

Method	Mixed models analysis
--------	-----------------------

Parameter estimate	Mean difference (final values)
--------------------	--------------------------------

Point estimate	-1.3
----------------	------

Confidence interval

level	95 %
-------	------

sides	2-sided
-------	---------

lower limit	-3.4
-------------	------

upper limit	0.9
-------------	-----

Variability estimate	Standard error of the mean
----------------------	----------------------------

Dispersion value	1.1
------------------	-----

---

<b>Statistical analysis title</b>	Change in PANSS Negative Symptom Subscale
-----------------------------------	---

Statistical analysis description:

Change from baseline to end of study

Comparison groups	Quetiapine 800 mg/day v Placebo
-------------------	---------------------------------

---

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.245
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	0.8
Variability estimate	Standard error of the mean
Dispersion value	1

### Secondary: CGI Severity of Illness total score

End point title	CGI Severity of Illness total score
End point description:	
Change	
End point type	Secondary
End point timeframe:	
Baseline to Day 42	

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	55	55	42	
Units: Number				
least squares mean (standard error)	-1.2 (± 0.1)	-1.3 (± 0.1)	-0.8 (± 0.2)	

### Statistical analyses

Statistical analysis title	Change in CGI Severity of Illness Score
Statistical analysis description:	
Change from baseline to end of study	
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.018
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-0.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	-0.1
Variability estimate	Standard error of the mean
Dispersion value	0.2

<b>Statistical analysis title</b>	Change in CGI Severity of Illness score
Statistical analysis description: Change from baseline to end of study	
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.104
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.2

<b>Secondary: CGI Global Improvement score</b>	
End point title	CGI Global Improvement score
End point description: Number of patients with improvement	
End point type	Secondary
End point timeframe: Day 42	

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	55	55	43	
Units: Participants	33	31	18	

## Statistical analyses

<b>Statistical analysis title</b>	CGI Global Improvement
Statistical analysis description:	
Percent of patients with improvement	
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.014
Method	GEE
Parameter estimate	Odds ratio (OR)
Point estimate	2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.2
upper limit	6

<b>Statistical analysis title</b>	CGI Global Improvement
Statistical analysis description:	
Percent of patients with improvement	
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.009
Method	GEE
Parameter estimate	Odds ratio (OR)
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	6.1

## Secondary: CGAS total score

End point title	CGAS total score
End point description:	
Change	
End point type	Secondary
End point timeframe:	
Baseline to Day 42	

End point values	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	65	63	65	
Units: Rating scale				
least squares mean (standard error)	13 ( $\pm$ 1.5)	14.9 ( $\pm$ 1.5)	9.9 ( $\pm$ 1.5)	

## Statistical analyses

Statistical analysis title	CGAS total score
Statistical analysis description: Change from baseline to end of study	
Comparison groups	Quetiapine 800 mg/day v Placebo
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.019
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	9.3
Variability estimate	Standard error of the mean
Dispersion value	2.1

Statistical analysis title	CGAS total score
Statistical analysis description: Change from baseline to end of study	
Comparison groups	Quetiapine 400 mg/day v Placebo
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.139
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	7.3
Variability estimate	Standard error of the mean
Dispersion value	2.1



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Safety Analysis Set (Number of Patients at Risk: Quetiapine 400 mg/day=73; Quetiapine 800 mg/day=74; Placebo=75, Total=222)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9
--------------------	---

### Reporting groups

Reporting group title	Quetiapine 400 mg/day
-----------------------	-----------------------

Reporting group description:

Quetiapine

Reporting group title	Quetiapine 800 mg/day
-----------------------	-----------------------

Reporting group description:

Quetiapine

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Serious adverse events	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 73 (5.48%)	5 / 74 (6.76%)	4 / 75 (5.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Nervous system disorders			
Schizophrenia			
subjects affected / exposed	1 / 73 (1.37%)	1 / 74 (1.35%)	1 / 75 (1.33%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aggression			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	1 / 75 (1.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucinations, visual			
subjects affected / exposed	1 / 73 (1.37%)	0 / 74 (0.00%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychotic Disorder			
subjects affected / exposed	1 / 73 (1.37%)	0 / 74 (0.00%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Agitation			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restlessness			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Verbal Abuse			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritability			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusions			
subjects affected / exposed	0 / 73 (0.00%)	0 / 74 (0.00%)	1 / 75 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 74 (0.00%)	1 / 75 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypersensitivity			
subjects affected / exposed	1 / 73 (1.37%)	0 / 74 (0.00%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Wound abscess			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Amoebiasis			
subjects affected / exposed	0 / 73 (0.00%)	1 / 74 (1.35%)	0 / 75 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			
subjects affected / exposed	0 / 73 (0.00%)	0 / 74 (0.00%)	1 / 75 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Quetiapine 400 mg/day	Quetiapine 800 mg/day	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	58 / 73 (79.45%)	55 / 74 (74.32%)	45 / 75 (60.00%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	20 / 73 (27.40%)	22 / 74 (29.73%)	5 / 75 (6.67%)
occurrences (all)	22	23	5
Headache			
subjects affected / exposed	6 / 73 (8.22%)	16 / 74 (21.62%)	14 / 75 (18.67%)
occurrences (all)	13	32	28
Dizziness			
subjects affected / exposed	6 / 73 (8.22%)	11 / 74 (14.86%)	4 / 75 (5.33%)
occurrences (all)	7	15	7
Insomnia			
subjects affected / exposed	9 / 73 (12.33%)	7 / 74 (9.46%)	17 / 75 (22.67%)
occurrences (all)	12	19	25
Agitation			

subjects affected / exposed occurrences (all)	6 / 73 (8.22%) 15	6 / 74 (8.11%) 20	10 / 75 (13.33%) 10
Sedation subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 5	4 / 74 (5.41%) 4	3 / 75 (4.00%) 3
Anxiety subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 5	3 / 74 (4.05%) 3	5 / 75 (6.67%) 13
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	4 / 74 (5.41%) 4	3 / 75 (4.00%) 4
Gastrointestinal disorders Dry mouth subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3	7 / 74 (9.46%) 7	1 / 75 (1.33%) 1
Increased appetite subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3	5 / 74 (6.76%) 5	3 / 75 (4.00%) 3
Nausea subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3	4 / 74 (5.41%) 6	13 / 75 (17.33%) 15
Vomiting subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 4	4 / 74 (5.41%) 4	6 / 75 (8.00%) 9

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 December 2006	Addition of CDRS-R

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported